MDA (Medical Devices Agency) reassures industry on fees in MCA (Medicines Control Agency) merger
This article was originally published in Clinica
Executive Summary
UK medical device manufacturers will not be subject to the fees that currently apply to their pharmaceutical counterparts when the two industries' regulatory bodies merge in April 2003 (see Clinica No 1012, pp 3-4). This reassurance was made by David Jefferys, chief executive of the (MDA), at the 10th annual conference on device regulation, hosted by the Association of British Health-Care Industries.